Literature DB >> 22488367

Suppression of signal transducers and activators of transcription 1 in hepatocellular carcinoma is associated with tumor progression.

Atsushi Hosui1, Peter Klover, Tomohide Tatsumi, Akio Uemura, Hiroaki Nagano, Yuichiro Doki, Masaki Mori, Naoki Hiramatsu, Tatsuya Kanto, Lothar Hennighausen, Norio Hayashi, Tetsuo Takehara.   

Abstract

Signal transducers and activators of transcription (STAT) 1 plays a pivotal role in cell-cycle and cell-fate determination, and vascular endothelial growth factor (VEGF) also contributes tumor growth. Recently, interferon (IFN) α has been reported to be effective for prevention of hepatocellular carcinomas (HCCs) recurrence, but the detailed mechanisms remain elusive. In vitro, cobalt chloride-treated VEGF induction and hypoxia responsive element (HRE) promoter activity were inhibited by IFNs and this abrogation was cancelled by introduction of small interfering RNA for STAT1. Immunoprecipitation/chromatin immunoprecipitation analyses showed STAT1 bound to hypoxia-inducible factor (HIF)-1α and dissociated HIF-complex from HRE promoter lesion. In a xenograft model using Balb/c nude mice, tumor growth was suppressed by IFNα through inhibition of VEGF expression and it was oppositely enhanced when STAT1-deleted cells were injected. This augmentation was due to upregulation of VEGF and hyaluronan synthase 2. In human samples, 29 HCCs were resected, divided into two groups based on STAT1 activation in tumor and the clinical features were investigated. Patients with suppressed STAT1 activity had a shorter recurrence-free survival. Histological and reverse transcriptase-polymerase chain reaction (RT-PCR) analyses showed portal vein microinvasion and increased VEGF levels in tumors from suppressed STAT1 group. These human samples also showed a reverse correlation between VEGF and STAT1-regulated genes expression. These results in vitro and in vivo suggested that IFNα are potential candidates for prevention of vessel invasion acting through inhibition of VEGF expression and need to be properly used when STAT1 expression is suppressed.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22488367      PMCID: PMC3541944          DOI: 10.1002/ijc.27580

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma.

Authors:  H Qin; J D Moellinger; A Wells; L J Windsor; Y Sun; E N Benveniste
Journal:  J Immunol       Date:  1998-12-15       Impact factor: 5.422

2.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

3.  The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer.

Authors:  Lishanthi Udabage; Gary R Brownlee; Susan K Nilsson; Tracey J Brown
Journal:  Exp Cell Res       Date:  2005-10-15       Impact factor: 3.905

4.  Rapid growth of hepatocellular carcinoma after or during interferon treatment of chronic hepatitis C: report of three cases.

Authors:  A Onitsuka; N Yamada; H Yasuda; T Miyata; T Kachi
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

5.  STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells.

Authors:  Joo Eun Jung; Hyun Gyu Lee; Ik Hyun Cho; Doo Hyun Chung; Sun-Hee Yoon; Young Mok Yang; Jung Weon Lee; Seongwon Choi; Jong-Wan Park; Sang-Kyu Ye; Myung-Hee Chung
Journal:  FASEB J       Date:  2005-05-26       Impact factor: 5.191

6.  Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

Authors:  Zofia von Marschall; Arne Scholz; Thorsten Cramer; Georgia Schäfer; Michael Schirner; Kjell Oberg; Bertram Wiedenmann; Michael Höcker; Stefan Rosewicz
Journal:  J Natl Cancer Inst       Date:  2003-03-19       Impact factor: 13.506

7.  Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas.

Authors:  R K Singh; M Gutman; C D Bucana; R Sanchez; N Llansa; I J Fidler
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

8.  Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions.

Authors:  K Shuai; C M Horvath; L H Huang; S A Qureshi; D Cowburn; J E Darnell
Journal:  Cell       Date:  1994-03-11       Impact factor: 41.582

9.  Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor.

Authors:  M Mise; S Arii; H Higashituji; M Furutani; M Niwano; T Harada; S Ishigami; Y Toda; H Nakayama; M Fukumoto; J Fujita; M Imamura
Journal:  Hepatology       Date:  1996-03       Impact factor: 17.425

10.  A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter.

Authors:  G Melillo; T Musso; A Sica; L S Taylor; G W Cox; L Varesio
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  6 in total

1.  Seaweed natural products modify the host inflammatory response via Nrf2 signaling and alter colon microbiota composition and gene expression.

Authors:  Michelle S Bousquet; Ranjala Ratnayake; Jillian L Pope; Qi-Yin Chen; Fanchao Zhu; Sixue Chen; Thomas J Carney; Raad Z Gharaibeh; Christian Jobin; Valerie J Paul; Hendrik Luesch
Journal:  Free Radic Biol Med       Date:  2019-09-16       Impact factor: 7.376

2.  Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway.

Authors:  Mi-Heon Lee; Puja Kachroo; Paul C Pagano; Jane Yanagawa; Gerald Wang; Tonya C Walser; Kostyantyn Krysan; Sherven Sharma; Maie St John; Steven M Dubinett; Jay M Lee
Journal:  J Cancer Sci Ther       Date:  2014-11-15

3.  A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis.

Authors:  Rioko Migita; Yasutaka Kimoto; Junki Hiura; Yuta Okumura; Takahiko Horiuchi
Journal:  Case Rep Rheumatol       Date:  2022-03-29

4.  Comprehensive analysis of the prognostic and immunotherapeutic implications of STAT family members in human colorectal cancer.

Authors:  Dingchang Li; Yanan Jiao; Wenxing Gao; Shidong Hu; Dingling Li; Wen Zhao; Peng Chen; Lujia Jin; Yingjie Zhao; Zhaofu Ma; Xiansheng Wu; Yang Yan; Wen Sun; Xiaohui Du; Guanglong Dong
Journal:  Front Genet       Date:  2022-08-19       Impact factor: 4.772

5.  A pan-cancer analysis of the expression of STAT family genes in tumors and their relationship to the tumor microenvironment.

Authors:  Min Zhou; Ping Zhang; Mengting Da; Rui Yang; Yulian Ma; Jiuda Zhao; Tao Ma; Jiazeng Xia; Guoshuang Shen; Yu Chen; Daozhen Chen
Journal:  Front Oncol       Date:  2022-09-13       Impact factor: 5.738

6.  Prognostic value of key genes of the JAK-STAT signaling pathway in patients with cutaneous melanoma.

Authors:  Fuqiang Pan; Qiaoqi Wang; Sizhu Li; Rui Huang; Xiangkun Wang; Xiwen Liao; Haiyan Mo; Liming Zhang; Xiang Zhou
Journal:  Oncol Lett       Date:  2020-01-10       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.